EXSCIENTIA AI LIMITED

1. EXSCIENTIA AI LIMITED 2021-08-18 → present
2. EXSCIENTIA LIMITED 2018-12-21 → 2021-08-18
3. EX SCIENTIA LIMITED 2012-07-20 → 2018-12-21

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have prepared and reviewed the financial projections for a period in excess of 12 months from the date of the approval of these Financial Statements for the Company and have a reasonable expectation that the Company has adequate resources to continue in business for the foreseeable future based on availability of funding from its ultimate parent company, Recursion. Recursion has confirmed to the Directors of the Company their intention and ability to continue to provide financial support to the Company for a period of at least 12 months from the date of approval of these financial statements.”

Group structure

1. EXSCIENTIA AI LIMITED · parent
   1. Kinetic Discovery Limited 100% · UK · Scientific services and drug research company
   2. Exscientia GmbH 100% · Austria · Artificial intelligence based precision medicine
   3. Exscientia Inc. 100% · US · Provision of technical expertise to Exscientia AI Limited
   4. Exscientia Ventures I, Inc 100% · US · holding company for the investment in the joint venture
   5. Exscientia Ventures II, Inc 100% · US · holding company for the investment in the joint venture

Significant events

• “On 7 February 2024, the Company announced the initiation of EXCYTE-2, an observational clinical study in acute myeloid leukaemia, or AML, to investigate the relationship between ex vivo drug response, measured in primary blood or bone marrow samples and actual patient clinical response.”
• “On 12 February 2024, our board of directors terminated the employment of Andrew Hopkins for cause and removed him as a Director of the company.”
• “On 17 July 2024, the Company and GT Apeiron Therapeutics Inc. ("Apeiron") announced that they had entered into an Asset Purchase Agreement, IP Assignment Agreement, Subscription Agreement and Share Surrender Agreement, pursuant to which the Company acquired the full rights to the intellectual property in GTAEX617.”
• “On 8 August 2024, Recursion Pharmaceuticals Inc (Recursion) and Exscientia Limited (formerly Exscientia plc) ("Exscientia) entered into a definitive agreement to create a global technology-enabled drug discovery leader with end-to-end capabilities.”
• “On 12 August 2024, the Company reached an agreement with the landlord of one of its leased premises to return the lease in question from that date. A payment of £700,000 was made upon the return of the lease, representing settlement of all outstanding obligations in relation to the premises.”
• “On 20 November 2024, Recursion acquired Exscientia's entire issued and to be issued share capital, combining to advance the industrialization of drug discovery.”
• “On 31 March 2025, the group parent company, Recursion Pharmaceuticals, Inc. acquired 49% of the share capital of Alpha Biotechnology GmbH ("Alpha"). Alpha in turn acquired 100% of the share capital of the Company's fully owned subsidiary, Exscientia GmbH for purchase consideration of £6.1m.”
• “On 30 May 2025, the Company reach an agreement with the landlord of one of its leased premises to assign three of its leases to a third party; with a further lease being assigned on 30 July 2025. As part of the agreement Exscientia sold office furniture and lab equipment to the third party for £2 million, creating a loss on disposal for the assets of £1.3 million.”
• “In June 2025, the Company announced a reduction in personnel program to help streamline the Company's operating strategy and post integration efficiencies. The Company has incurred approximately £1.4 million of charges in relation to the workforce reduction in calendar 2025.”
• “In July 2025, the Company's fully owned subsidiary, Exscientia Ventures I, Inc. entered into a membership interest purchase agreement (the Purchase Agreement) to acquire Rallybio Corporation's ("Rallybio") full interest in Exscientia Al Limited and Rallybio's joint ENPP1 inhibitor program (REC-102) and an associated backup molecule for the treatment of hypophosphatasia (HPP).”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -55.9%

  £19,975,000 → £8,818,000

• Cash

  +30.9%

  £5,193,000 → £6,796,000

• Net assets

  -19,572.5%

  £919,000 → -£178,952,000

• Employees

  -10.2%

  392 → 352

• Operating profit

  -35.4%

  -£148,985,000 → -£201,796,000

• Profit before tax

  -38.9%

  -£145,474,000 → -£202,090,000

• Wages

  -4.9%

  £38,819,000 → £36,933,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers